It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
The review found no eligible studies for this question.
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).
Budesonide may leads to higher clinical response compared with mesalazine (low certainty).
Budesonide may leads to higher histological response compared with mesalazine (low certainty).
Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).
Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in maintenance of remission compared with mesalazine or sulfasalazine (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).